SystImmune to Receive Milestone Payment from Bristol Myers Squibb Under Iza-Bren CollaborationPRNewsWire • 10/13/25
Bristol Myers Squibb Strengthens and Diversifies Cell Therapy Portfolio with Acquisition of Orbital TherapeuticsBusiness Wire • 10/10/25
Bristol Myers Squibb and TV Host Gail Simmons Tackle Stigma in Schizophrenia with New Initiative Spotlighting the Power of Support and ConnectionBusiness Wire • 10/10/25
Bristol Myers Squibb's Anti-MTBR-Tau-Targeting Antibody, BMS-986446, Granted Fast Track Designation by U.S. FDA for the Treatment of Alzheimer's DiseaseBusiness Wire • 10/01/25
Bristol Myers Squibb (BMY) Beats Stock Market Upswing: What Investors Need to KnowZacks Investment Research • 09/30/25
7 Ideal "Safer" Dividend Buys From 61 September Graham Value All-Stars (GVAS)Seeking Alpha • 09/30/25
Buy 7 Barron's Better Bets (Than T-Bills) From 15 'Safer' Of 23 September Dividend DogsSeeking Alpha • 09/28/25
Bristol Myers Squibb Builds on Eliquis® (apixaban) Direct-to-Patient Program, Announces New BMS Patient Connect Platform Offering Sotyktu® (deucravacitinib)Business Wire • 09/25/25
BMY Reports Positive Data From a Late-Stage Multiple Myeloma StudyZacks Investment Research • 09/24/25
Bristol-Myers Squibb Company (BMY) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum TranscriptSeeking Alpha • 09/23/25
Bristol Myers Squibb Announces Phase 3 EXCALIBER-RRMM Study Evaluating Iberdomide in Combination with Standard Therapies Demonstrated a Significant Improvement in Minimal Residual Disease Negativity Rates in Relapsed or Refractory Multiple MyelomaBusiness Wire • 09/23/25